Natural killer/T (NK/T) cell lymphoma is a distinct lymphoid neoplasm with aggressive course and poor outcomes. Optimal treatment strategies for advanced NK/T cell lymphoma have not been fully defined. We carried out a randomized, open-label, multicenter clinical trial enrolled patients with newly diagnosed in stage III-IV NK/T cell lymphoma to compare the safety and efficacy of DDGP and SMILE.
Introduction
Extranodal natural killer/T-cell lymphoma (ENKL) is a rare, distinctive clinicopathological disease entity with aggressive clinical feature and strong association with Epstein-Barr virus infection. It is much more frequent in Asian and Latin American countries than in Western countries (1) . NK cells express high concentrations of the multidrug-resistant P-glycoprotein (P-gp), so that anthracycline-containing regimens, such as CHOP and CHOP-like regiments usually provide poor clinical outcomes (2) (3) (4) . Recently, a L-asparaginase (L-Asp) based regimen including dexamethasone, methotrexate, ifosfamide, L-Asp and etoposide (SMILE) has been devised to tackle these problems. It brought higher response rate, prolonged overall survival (OS) and progression-free survival (PFS) than anthracycline-containing regimens. But at the same time, severe hematologic toxicity leaded serious chemotherapy-related infection or even death. Up to 92% of patients were at risk of undergoing a grade 4 neutropenia. Allergic reactions also happened in half of patients (5, 6) .
Additionally, the short plasma half-life of L-Asp causes frequent dosing which adds the patients' suffering. Physicians were looking for new chemotherapeutic regimens with high efficacy and low toxicity for ENKL. In our previously prospective and retrospective studies, Li L et al. showed that patients with newly diagnosed stage II-IV ENKL who were initially treated with a DDGP regimen had a complete remission (CR) rate of 83.3% and partial remission (PR) rate of 16.7%(7). Zhou Z et al.
conducted a study and showed 17 relapsed/refractory ENKL patients treated with DDGP regimen had a overall response rate (ORR) of 88.2 % (8). Currently, there was no article comparing the efficacy, toxicity and survival analysis of DDGP versus SMILE regimens in newly diagnosed advanced stage NK/T cell Lymphoma. Based on our previous studies, we designed this randomized controlled trial.
Methods

Study design and patient eligibility
This randomized controlled, open-label, multicenter study compared the efficacy and safety of DDGP regimen with SMILE in patients with newly diagnosed ENKL in III-IV stages. The trial was registered on the 
Assessment of adverse effects
Adverse reactions were monitored by biochemistry and hematological tests, urinalysis, electrocardiogram and routine physical examination.
They were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 and assessed from the first cycle of the regimen until one month after terminal treatment (13) .
Statistical analysis
The primary endpoint was PFS, which was defined as the interval from date of randomization to the date of disease progression or date of death, whichever occurred first, irrespective of the use of subsequent antineoplastic therapy. Patients who were progression-free and alive were censored at the time of their last disease assessment, and patients who were alive with no post-baseline disease assessment were censored at randomization. Secondary endpoints included ORR (CR and PR), OS and safety.
We compared the clinical and laboratory data, response rate, and adverse effects between DDGP group and SMILE group by Chi-squared 
Result Baseline characteristics of patients
Forty-two patients were enrolled from March 2011 to June 2014. Their baseline characteristics are listed in Table 2 . The median age was 42 years (range, 14 to 64 years) and the male: female ratio was 1.625:1. 90% of the patients were diagnosed as upper aerodigestive tract ENKL. 38% of the cases had newly diagnosed stage IV disease. Systemic B symptoms were present in 20 patients (48%) and the elevation of LDH level was observed in 19 patients (45%). Between the DDGP (21cases) and SMILE (21cases) groups, there were no obvious differences in the baseline characteristics of patients.
Treatment
The mean cycles of chemotherapy for patients receiving DDGP was 5.57 cycles (range, 2 to 6 cycles), whereas for those receiving SMILE, it 
Response
The ORR in DDGP group was obviously better than SMILE group (95% versus 67%, P =0.018), with CR and PR rates of 71% and 24% for DDGP whereas 29% and 38% for SMILE (Table 3) . 
OS and PFS
The DDGP arm had a significantly better OS and PFS than SMILE arm: 90% versus 57% for 1-year OS, 74% versus 45% for 2-year OS and 86% versus 38% for 1-year PFS, respectively (Fig1).
The univariate analysis of OS (Table 4) showed that only site of involvement at diagnosis was predictor of OS in the 42 patients.
Adverse events
Adverse events were assessed in all patients (Table 5 ). Adverse events included hematologic and non-hematologic adverse reaction. Compared with the DDGP arm, the SMILE arm had more instances of grade 3/4 leukopenia (P =0.030) and grades 3/ 4 allergy (P =0.015). Moreover, 3cases underwent grade 3 diarrhea and 2 cases underwent grade 4 mucositis which leaded the patients to death in the SMILE arm. At the same time, 2 patients had a grade 4 heart failure and 1 patient had a grade 3 arrhythmia in the SMILE group. However, there were more instances of grade 3/4 anemia (P =0.039) in DDGP arm than SMILE arm.
Discussion
ENKL was labeled with high invasiveness, easy to develop drug resistance, low curative effect, dismal prognosis, and short survival time.
Though physicians conducted many clinical trials, there was no optimal suffering of patients (21, 23, 24) .
Currently, the safety and effectiveness of PEG-Asp against ENKL had been confirmed by some reports (7, 8, 25) Gemcitabine is a novel nucleoside analogue which inhibit DNA synthesis. Gemcitabine-containing therapy shown promising results in patients with ENKL. Ahn HK et al. showed that 20 patients with refractory or relapsed ENKL were given gemcitabine-containing regimen.
The ORR was 40% with a CR rate of 20%. Four complete responders had a disease-free status for more than 7 months (27) . A retrospectively study showed that for the 93 patients newly diagnosed with stage IE to IIE ENKL, patients in GELOX (Gemcitabine, Oxaliplatin, and L-Asp) group had higher CR rate and ORR than those in the EPOCH group (70.0% vs. 41 .5%, P =0.007 for CR rate; 87.5% vs. 67.9%, P =0.047 for ORR). The GELOX regimen resulted in significantly superior 5-year PFS (79.0% vs.
46.5%, P =0.005) and OS (78.9% vs. 50.4%, P =0.003) rates. And the toxicity of both regimens was acceptable (28) .
But until now, there have not been any prospective clinical trials to compare DDGP and SMILE regimens in the side effects and efficacy.
Thus, we designed this randomized controlled trial and found that DDGP group showed prolonged PFS and OS than SMILE group. The ORR and CR rate in DDGP group was also higher than that in SMILE group.
Moreover, SMILE group had a higher incidence of leucopenia, allergic reaction, nephrotoxicity, diarrhea, cardiotoxicity, and mucositis. The major side effects of DDGP regimen were myelosuppression and coagulation abnormalities. Though there was no drug-related death, we need careful handle the DDGP-associated anemia and thrombocytopenia.
In conclusion, our study demonstrated that DDGP regimen can result in a higher CR rate, a longer survival time, and a lower toxicity than SMILE regimen. This regimen offers a much safer and much more effective regimen for ENKL stage III/IV patients.
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